Sponsors (6)
The bill improves allied biosurveillance and NATO biodefense coordination to reduce biological threats, but does so at the cost of added compliance burdens, potential research slowdowns, higher taxpayer spending, and possible limits on international scientific collaboration.
Hospitals, public-health systems, and researchers will get improved biosurveillance and coordinated detection/response across human, animal, plant, and environmental health, enabling earlier outbreak identification and faster response.
U.S. diplomats, NATO members, and state governments will have strengthened biodefense planning and coordination, improving collective detection, response, and recovery capabilities for biological incidents.
Taxpayers and the international community could see reduced risks from misuse of biotechnology because the bill promotes coordinated export controls and international standards that limit access to items enabling military or malicious use.
Researchers and laboratories (including hospitals) could face slower legitimate research and higher compliance costs due to tighter export controls and restrictions on dual‑use biotech.
U.S. taxpayers could face increased spending or reallocated resources to expand NATO biodefense activities and allied capabilities, potentially diverting funds from other domestic priorities.
International scientific collaboration and data sharing may be complicated for researchers and foreign collaborators by stronger export controls and coordinated restrictions, harming joint research and innovation.
Based on analysis of 2 sections of legislative text.
Directs the Secretary of State to strengthen U.S. cooperation with NATO and allies on biodefense, biosecurity, and biotechnology and to produce two named international cooperation strategies.
Introduced February 23, 2026 by Keith Self · Last progress February 23, 2026
Requires the Secretary of State to lead U.S. efforts to strengthen cooperation with NATO and other allies and partners on biodefense, biosecurity, and biotechnology. Directs the State Department (via the Under Secretary for Arms Control and International Security, and in coordination with relevant officials) to promote interoperability, resilience, detection, attribution, emergency response and recovery, and higher biosafety/biosecurity standards among allies and to evaluate NATO policy and capability adjustments. Directs the Secretary to produce two detailed strategies: a NATO Biodefense Strategy assessing current U.S.–NATO cooperation and gaps, and an International Biotechnology, Biosecurity, and Biodefense Cooperation Strategy proposing commitments or agreements with allies (explicitly including major non‑NATO allies) and assessing the feasibility of coordinating export controls for biotechnology items that could pose national‑security risks for military end uses.